Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Martin R. Weihrauch"'
Autor:
Marlen Runz, Daniel Rusche, Stefan Schmidt, Martin R. Weihrauch, Jürgen Hesser, Cleo-Aron Weis
Publikováno v:
Diagnostic Pathology, Vol 16, Iss 1, Pp 1-10 (2021)
Abstract Background Histological images show strong variance (e.g. illumination, color, staining quality) due to differences in image acquisition, tissue processing, staining, etc. This can impede downstream image analysis such as staining intensity
Externí odkaz:
https://doaj.org/article/035c13716146415d9df151fca1cd80f4
Autor:
Marc Beyer, Sabine Classen, Elmar Endl, Matthias Kochanek, Martin R. Weihrauch, Svenja Debey-Pascher, Percy A. Knolle, Joachim L. Schultze
Publikováno v:
Clinical and Developmental Immunology, Vol 2011 (2011)
In recent years an increase of functional CD4+CD25+ regulatory T cells (Treg cells) has been established for patients with solid tumors, acute leukemias, and lymphomas. We have reported an expanded pool of CD4+CD25high Treg cells in patients with ch
Externí odkaz:
https://doaj.org/article/4eaa9cd671a54d299d9c3d93bb65ba84
Autor:
Jürgen Hesser, Martin R. Weihrauch, Daniel Rusche, Stefan Schmidt, Marlen Runz, Cleo-Aron Weis
Publikováno v:
Diagnostic Pathology, Vol 16, Iss 1, Pp 1-10 (2021)
Diagnostic Pathology
Diagnostic Pathology
Background Histological images show strong variance (e.g. illumination, color, staining quality) due to differences in image acquisition, tissue processing, staining, etc. This can impede downstream image analysis such as staining intensity evaluatio
Autor:
Thomas R. Weihrauch, Hans-Christoph Diener, Justus Duyster, Matthias Girndt, Viola Hach-Wunderle, Dieter Häussinger, Uta C. Hoppe, Carl M. Kirchmaier, Hartmut Lode, Elisabeth Märker-Hermann, Christoph M. Niederau, Thomas Poralla, Kurt Rasche, Martin Ruß, Werner A. Scherbaum, Helmut Schinzel, Matthias Schott, Ralf Stahlmann, Petra A. Thürmann, Raymond Voltz, Martin R. Weihrauch, Annette Welz-Barth, René R. Wenzel, Eberhard Windler, Thomas Zander, B.-Chr. Zyriax, Jürgen Heinz, Brigitte M. Lobnig, Benedikt C. Ostendorf, Daniele Pillitteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fc69ea089ce702ac41727c6217b68c4
https://doi.org/10.1016/b978-3-437-41655-2.01002-2
https://doi.org/10.1016/b978-3-437-41655-2.01002-2
Autor:
Thomas R. Weihrauch, Hans-Christoph Diener, Justus Duyster, Matthias Girndt, Viola Hach-Wunderle, Dieter Häussinger, Uta C. Hoppe, Carl M. Kirchmaier, Hartmut Lode, Elisabeth Märker-Hermann, Christoph M. Niederau, Thomas Poralla, Kurt Rasche, Martin Ruß, Werner A. Scherbaum, Helmut Schinzel, Matthias Schott, Ralf Stahlmann, Petra A. Thürmann, Raymond Voltz, Martin R. Weihrauch, Annette Welz-Barth, René R. Wenzel, Eberhard Windler, Birgit-Christiane Zyriax, Jürgen Heinz, Brigitte M. Lobnig, Benedikt C. Ostendorf, Daniele Pillitteri, Thomas Rotthoff
Publikováno v:
Lehrbuch Homöopathie: Grundlagen und Praxis der klassischen Homöopathie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc5e88aadb8305a66fc0681887b36b45
https://doi.org/10.1016/b978-3-437-41654-5.01002-1
https://doi.org/10.1016/b978-3-437-41654-5.01002-1
Publikováno v:
European journal of haematology. 97(4)
Background For the histopathological diagnosis of lymphoma, lymph node excision biopsies are regarded as standard of care. In contrast, for the diagnosis of carcinoma and deep-seated tumors, core needle biopsies (CNBs) are accepted as a sufficient sa
Autor:
Thomas R. Weihrauch, Hans-Christoph Diener, Justus Duyster, Matthias Girndt, Viola Hach-Wunderle, Dieter Häussinger, Uta C. Hoppe, Carl M. Kirchmaier, Hartmut Lode, Elisabeth Märker-Hermann, Christoph M. Niederau, Thomas Poralla, Kurt Rasche, Martin Ruß, Werner A. Scherbaum, Helmut Schinzel, Matthias Schott, Ralf Stahlmann, Petra A. Thürmann, Raymond Voltz, Martin R. Weihrauch, Annette Welz-Barth, René R. Wenzel, Eberhard Windler, Birgit-Christiane Zyriax, Jürgen Heinz, Brigitte M. Lobnig, Benedikt C. Ostendorf, Daniele Pillitteri, Thomas Rotthoff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0eea4ab820f62885eba68ece8ba2916
https://doi.org/10.1016/b978-3-437-41653-8.01002-0
https://doi.org/10.1016/b978-3-437-41653-8.01002-0
Autor:
Thomas Zander, Hans-Christoph Diener, Ralf Stahlmann, Jürgen Heinz, Christoph M. Niederau, Matthias Schott, Petra A. Thürmann, Martin R. Weihrauch, Annette Welz-Barth, René R. Wenzel, Kurt Rasche, Brigitte M. Lobnig, Thomas R. Weihrauch, Matthias Girndt, Benedikt Ostendorf, Helmut Schinzel, Elisabeth Märker-Hermann, Hartmut Lode, Justus Duyster, Carl M. Kirchmaier, Raymond Voltz, Martin Ruß, Daniele Pillitteri, Dieter Häussinger, Werner A. Scherbaum, Eberhard Windler, Uta C. Hoppe, Viola Hach-Wunderle, Thomas Poralla, B.-Chr. Zyriax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d525964d26b978539fa0ec6f5d42b14
https://doi.org/10.1016/b978-3-437-24275-5.01002-2
https://doi.org/10.1016/b978-3-437-24275-5.01002-2
Publikováno v:
Expert Opinion on Investigational Drugs. 20:361-372
Toll-like receptor 9 (TLR9) agonists, commonly referred to as CpG oligodeoxynucleotides (ODN), have been added to the arsenal of anti-cancer drugs as monotherapy or in combination with chemotherapy, radiotherapy and other immunotherapeutic approaches